ERBB2 and breast carcinoma: While trastuzumab exacerbates anthracycline-related cardiac damage (An and Sheikh, 2019), meta-analyses indicate that its concurrent use with epirubicin enhances pCR rates in HER2-positive breast cancer without significantly increasing cardiotoxicity, though caution is needed in hormone receptor-positive cases (Yang et al., 2024).